ARTICLE https://harbor-dev.pubfactory.com/view/journals/jnccn/15/8/article-pxxvii.xml NCCN News 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/15/8/article-pxxxv.xml Oncology Research Program 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/15/8/article-p973.xml When It's Really Good, We Know It! 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/15/8/article-p975.xml To the Editor: How Do We Solve This Confusion? 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/15/8/article-p978.xml Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/15/8/article-p989.xml NCCN Guidelines Insights: Palliative Care, Version 2.2017 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/15/8/article-p998.xml Race- and Sex-Based Disparities in the Therapy and Outcomes of Squamous Cell Carcinoma of the Anus 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/15/8/article-p1005.xml The Evolution of Metastatic Colorectal Cancer Clinical Trials: Application of the ASCO Framework for Assessing Value 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/15/8/article-p1015.xml Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/15/8/article-p1022.xml Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993–2013 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/15/8/article-p1028.xml Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/15/8/article-p1063.xml DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/15/8/article-p1070.xml Trends in Neoadjuvant Approaches in Pancreatic Cancer 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/15/8/article-p983.xml Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer 2019-01-04 https://harbor-dev.pubfactory.com/view/journals/jnccn/15/8/article-p1078.xml Acting on Rare Driver Alterations: Is Getting a Meaningful Response a Game of Chance or Scientific Rigor? 2019-01-04